Reports Q2 revenue $20.5M vs. $23.1M last year. “We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first-hand the dedication of our team. The fundamentals of the business remain intact with attractive margins and promising technologies serving high-growth markets,” said John Duke, President and CEO. “Our priorities are to grow our core business and re-structure our balance sheet. We are taking immediate actions on both fronts and expect these actions to position us well for revenue growth and margin expansion in 2026 and beyond.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- HBIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Harvard Bioscience: Strong Q2 Performance and Strategic Leadership Changes Drive Buy Rating
- Harvard Bioscience Announces CEO Succession Plan
- Harvard Bioscience announces CEO succession plan, appointment of two directors
- Harvard Bioscience Faces Nasdaq Compliance Challenge